Particle.news
Download on the App Store

Oval Office Fainting Halts Trump GLP‑1 Drug Announcement, Event Resumes

The White House said the guest received immediate care from its medical team, with his condition described as okay.

Overview

  • A man standing behind President Trump collapsed as Eli Lilly CEO David Ricks spoke, prompting the press to be ushered out before the briefing restarted roughly 30 minutes later with Trump saying the participant was fine.
  • Dr. Mehmet Oz and others assisted the man to the floor and the White House Medical Unit responded, while no cause for the fainting was disclosed in initial reports.
  • Reporters initially identified the individual as Novo Nordisk executive Gordon Findlay, but the company later said Findlay was not present and named Mike Doustdar and Dave Moore as its only representatives in the room.
  • The event detailed agreements with Eli Lilly and Novo Nordisk to lower prices and expand access for GLP‑1 weight‑loss drugs, including Wegovy and Zepbound.
  • Officials highlighted discounted pathways such as pill versions projected at $149 per month pending FDA approval and reduced injectable costs for Medicare and Medicaid through a planned TrumpRx platform.